Page last updated: 2024-08-17

adenosine monophosphate and Coronary Occlusion

adenosine monophosphate has been researched along with Coronary Occlusion in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (33.33)	24.3611
2020's	2 (66.67)	2.80

Authors

Authors	Studies
Canonico, ME; Parodi, G; Saba, PS; Siciliano, R; Talanas, G	1
Agostini, C; Bernardo, P; Caniato, F; Cappelli, F; Di Filippo, C; Di Mario, C; Mattesini, A; Meucci, F; Sori, A; Stolcova, M	1
Bhatt, DL; Day, JRS; Gibson, CM; Hamm, CW; Mahaffey, KW; Parker, WA; Prats, J; Price, MJ; Steg, PG; Stone, GW; Storey, RF; White, HD	1

Trials

1 trial(s) available for adenosine monophosphate and Coronary Occlusion

Article	Year
Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study. Thrombosis and haemostasis, 2017, 06-02, Volume: 117, Issue:6 Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Occlusion; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Dyspnea; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; Percutaneous Coronary Intervention; Receptors, Purinergic P2Y12; Survival Analysis; Ticlopidine; Treatment Outcome; Withholding Treatment	2017

Article

Year

Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study.

Thrombosis and haemostasis, 2017, 06-02, Volume: 117, Issue:6

Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Occlusion; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Dyspnea; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; Percutaneous Coronary Intervention; Receptors, Purinergic P2Y12; Survival Analysis; Ticlopidine; Treatment Outcome; Withholding Treatment

2017

Other Studies

2 other study(ies) available for adenosine monophosphate and Coronary Occlusion

Article	Year
Cangrelor-supported primary percutaneous coronary intervention in a patient with cardiogenic shock due to left main acute occlusion. Journal of cardiovascular medicine (Hagerstown, Md.), 2020, Volume: 21, Issue:8 Topics: Adenosine Monophosphate; Coronary Occlusion; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Shock, Cardiogenic; Treatment Outcome	2020
Discontinuation of both cangrelor and ticagrelor because of severe dyspnea during primary angioplasty. Journal of cardiovascular medicine (Hagerstown, Md.), 2021, 04-01, Volume: 22, Issue:4 Topics: Adenosine Monophosphate; Aged; Anxiety; Chest Pain; Coronary Angiography; Coronary Occlusion; Drug Substitution; Drug-Eluting Stents; Drug-Related Side Effects and Adverse Reactions; Dyspnea; Electrocardiography; Humans; Inferior Wall Myocardial Infarction; Male; Percutaneous Coronary Intervention; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome; Withholding Treatment	2021

Article

Year

Cangrelor-supported primary percutaneous coronary intervention in a patient with cardiogenic shock due to left main acute occlusion.

Journal of cardiovascular medicine (Hagerstown, Md.), 2020, Volume: 21, Issue:8

Topics: Adenosine Monophosphate; Coronary Occlusion; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Shock, Cardiogenic; Treatment Outcome

2020

Discontinuation of both cangrelor and ticagrelor because of severe dyspnea during primary angioplasty.

Journal of cardiovascular medicine (Hagerstown, Md.), 2021, 04-01, Volume: 22, Issue:4

Topics: Adenosine Monophosphate; Aged; Anxiety; Chest Pain; Coronary Angiography; Coronary Occlusion; Drug Substitution; Drug-Eluting Stents; Drug-Related Side Effects and Adverse Reactions; Dyspnea; Electrocardiography; Humans; Inferior Wall Myocardial Infarction; Male; Percutaneous Coronary Intervention; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome; Withholding Treatment

2021